Skip to main content
Journal cover image

CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)

Publication ,  Conference
Desjardins, A; Chandramohan, V; Landi, D; Peters, KB; Johnson, M; Khasraw, M; Low, J; Threatt, S; Bullock, C; Herndon, JEII; Lipp, ES ...
Published in: NEURO-ONCOLOGY
2022

Duke Scholars

Published In

NEURO-ONCOLOGY

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2022

Volume

24

Issue

7

Start / End Page

vii65 / vii65

Location

Tampa Convention Center, Tampa Bay, F L

Conference Name

2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Chandramohan, V., Landi, D., Peters, K. B., Johnson, M., Khasraw, M., … Bigner, D. (2022). CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS). In NEURO-ONCOLOGY (Vol. 24, pp. vii65–vii65). Tampa Convention Center, Tampa Bay, F L. https://doi.org/10.1093/neuonc/noac209.255
Desjardins, Annick, Vidya Chandramohan, Daniel Landi, Katherine B. Peters, Margaret Johnson, Mustafa Khasraw, Justin Low, et al. “CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS).” In NEURO-ONCOLOGY, 24:vii65–vii65, 2022. https://doi.org/10.1093/neuonc/noac209.255.
Desjardins A, Chandramohan V, Landi D, Peters KB, Johnson M, Khasraw M, Low J, Threatt S, Bullock C, Herndon JEII, Lipp ES, Sampson J, Friedman A, Friedman HS, Ashley D, Knorr D, Ravetch J, Bigner D. CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS). NEURO-ONCOLOGY. 2022. p. vii65–vii65.
Journal cover image

Published In

NEURO-ONCOLOGY

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2022

Volume

24

Issue

7

Start / End Page

vii65 / vii65

Location

Tampa Convention Center, Tampa Bay, F L

Conference Name

2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences